Get the app
USHealthcare

Bausch + Lomb Corp (BLCO)

US · Healthcare · Medical Instruments & Supplies

$16.77-1.76%
Last close · 2026-09-17

Latest quarter · ended 2026-06-30

Revenue
$1.39B
Revenue YoY
+8.7%
Net profit
$-14.0M
EPS
$0.16
EPS estimate
$0.16
Net margin
-1.0%

EPS came in at 0.16 against a street estimate of 0.16 — a beat of 0.0%.

Key statistics

Market cap
$6.16B
Forward P/E
11.5
P/B
0.97
Book value
$18.09
EPS (TTM)
$-0.48
52-week high
$18.91
52-week low
$13.77
50-day MA
$16.91
200-day MA
$16.61
Beta
0.56

Analyst view

Analysts rate Bausch + Lomb Corp a buy (6 buy, 8 hold, 1 sell out of 15) with an average price target of $18.62.

From the latest earnings call · 2026-07-29

CONFIDENT BLCO delivered 8% constant currency revenue growth and 28% EBITDA growth in Q2, raising full-year guidance. Surgical surged 16%, Pharma 14%, Vision Care 4%. Net leverage improved to 4.7x. Strong cash conversion and pipeline momentum underscore confidence in 2028 targets. Q2 2026 Contact lens portfolio showed balanced global growth. Canada +11%, Asia Pacific +3%. Consumer pressure tracked gas prices. Analysts pressed on three-year plan credibility (Saunders: delivered 4 quarters, broad metrics improving), surgical post-recall momentum (momentum real, not catch-up), and H2 comp toughness (seasonality, fundamental momentum offset comps). Management emphasized say-do consistency and structural durability. 2026-07-29…

Full summary in the app.

Shareholding

Insiders
87.30%
Institutions
11.14%

Largest institutional holders

FundStake
Deutsche Bank AG0.99%
ICAHN CARL C0.98%
Oaktree Capital Management LLC0.95%
D. E. Shaw & Co LP0.93%
Goldentree Asset Management LP0.74%
Davidson Kempner Capital Management LP0.62%
Caspian Capital Partners, L.P.0.56%
Glenview Capital Management LLC0.54%

Recent filings & reports

DocumentDate
Material agreement · Q3 2026
BAUSCH + LOMB CORPORATION - FORM 8-K SUMMARY BUSINESS & SEGMENT HIGHLIGHTS • Bausch + Lomb Corporation (ticker: BLCO) is a Canadian-incorporated com
2026-08-06
Quarterly report · Q2 2026
BAUSCH + LOMB CORPORATION - Q2 2026 10-Q SUMMARY HEADLINE NUMBERS • Reporting Period: Quarter ended June 30, 2026 • Company Incorporation: Canada •
2026-07-29
Results announced · Q3 2026
BAUSCH + LOMB Q2 2026 EARNINGS SUMMARY HEADLINE NUMBERS • Q2 2026 revenue: $1.394 billion (up 9% reported, 8% constant currency vs. Q2 2025) • GAAP
2026-07-29
Shareholder vote results · Q2 2026
BAUSCH + LOMB CORPORATION – 8-K SUMMARY HEADLINE NUMBERS • Annual Meeting of Shareholders held May 20, 2026 • Total votes cast for director election
2026-05-20
Quarterly report · Q1 2026
BAUSCH + LOMB CORPORATION – FORM 10-Q SUMMARY For Quarter Ended March 31, 2026 --- HEADLINE NUMBERS • Company: Bausch + Lomb Corporation, headquart
2026-04-29
Results announced · Q2 2026
BAUSCH + LOMB Q1 2026 RESULTS SUMMARY HEADLINE NUMBERS • Total revenue: $1.244 billion for Q1 2026 vs. $1.137 billion in Q1 2025 • Revenue growth: 9
2026-04-29
Proxy statement · Q2 2026
BAUSCH + LOMB CORPORATION – 2026 PROXY STATEMENT SUMMARY CEO TOTAL COMPENSATION • CEO Brenton L. Saunders' exact 2025 compensation figure is not sta
2026-04-10
Annual report FY2025
BAUSCH + LOMB CORPORATION – FORM 10-K SUMMARY Fiscal Year Ended December 31, 2025 --- HEADLINE NUMBERS • Shares Outstanding: 354,318,198 common sha
2026-02-18

Readable in the app.

Deals & corporate news

AnnouncementDate
Raises full-year 2026 revenue and adjusted EBITDA guidance
Bausch + Lomb reported strong Q2 2026 results with revenue of $1.394 billion, up 9% year-over-year (8% on constant currency basis). The company raised its full-year 2026 guidance for both re
2026-07-29
Raises full-year 2026 revenue and adjusted EBITDA guidance based on strong Q1
Bausch + Lomb reported strong Q1 2026 results with revenue of $1.244 billion, up 9% year-over-year (6% excluding favorable currency effects). The company raised full-year 2026 guidance based
2026-04-29
Q4 and full-year 2025 results announced; 2026 guidance provided
Bausch + Lomb reported strong fourth-quarter and full-year 2025 results with solid revenue growth and improved profitability. The company generated $1.405 billion in Q4 revenue (10% growth r
2026-02-18
Three-year financial targets and fiscal year 2025 guidance reaffirmed at Investor Day
Bausch + Lomb held an Investor Day on November 13, 2025, where management announced three-year financial targets, discussed pipeline products in development, and reaffirmed its full-year 202
2025-11-13
Q3 2025 results and updated full-year adjusted EBITDA guidance
Bausch + Lomb reported Q3 2025 revenue of $1.281 billion, up 7% year-over-year (6% in constant currency), exceeding expectations with broad-based growth across all three segments. The compan
2025-10-29

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Bausch + Lomb Corp — free to start.

Google PlayApp Store

Other Healthcare companies

Data updated 2026-09-18.